Synlogic granted fda fast track designation for synb1353 for the treatment of homocystinuria (hcu)

Cambridge, mass., aug. 23, 2022 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that the u.s. food and drug administration (fda) has granted fast track designation to synb1353 for the potential treatment of homocystinuria (hcu).
SYBX Ratings Summary
SYBX Quant Ranking